Back to search results

e-ALIGN: Aligning Medications for Dementia and MCI

This study, called e-ALIGN, is testing a new way to help older adults with mild cognitive impairment (MCI) or dementia, and their caregivers, manage medications. The intervention, e-ALIGN Patient-Portal Deprescribing, provides educational materials through a patient portal before a doctor's visit. A pharmacist will also help align medications with your goals and reduce the use of certain potentially inappropriate medicines (PIMs) that affect the brain and nervous system (CNS). We are looking for people aged 65 and older with MCI or dementia who use a patient portal, along with their caregivers. Success in this study means seeing how many people open the messages, watch the videos, and find the educational videos acceptable, all measured one month after the messages are sent. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 100 participants. It is testing an intervention delivered through a patient portal and by a pharmacist.
What's involved
The intervention involves receiving educational materials through a patient portal and a pharmacist-led discussion. The study measures engagement with these materials one month after they are sent.
Compensation
Not stated in the trial record.
Follow-up
Participants' engagement with the educational materials is measured at 1 month after the messages are sent.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07454824

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

Recruiting
NAAges 65+InterventionalHealth services
Johns Hopkins University
~100 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:e-ALIGN Patient-Portal Deprescribing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients who open the patient portal message
Measured over 1 month after sending message
+2 more outcomes measured

Conditions

Dementia
Potentially Inappropriate Medication Use
Mild Cognitive Impairment (MCI)

Explore related trials

DementiaMild cognitive disorder

NCT07454824

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins Community Physicians

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ariel Green, MD, MPH, PhD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Ariel Green, MD, MPH, PhD
[email protected]
410-550-6733
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients: Age ≥65, with a diagnosis of MCI or dementia based on ICD-10 codes and ≥1 active CNS-PIM, who are active patient portal users.
Family or other companions \>21 years who regularly help the patient with managing medications.

Exclusion

As the trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded.

What this trial measures

  • Number of patients who open the patient portal message1 month after sending message

    The investigators will assess the number of patients and/or care partners who read the patient portal message sent by the study team, which invites the participant to meet with a clinical pharmacist for deprescribing.

  • Number of patients who watch the video1 month after sending message

    The investigators will assess the number of patients who click and watch the educational video about CNS-PIM and deprescribing.

  • Acceptability of educational video assessed by survey1 month after sending message

    The investigators will assess the acceptability of the educational video by administering a survey to participants. The survey will ask participants to rate various features of the video on a 5-point Likert scale, where a higher score indicates greater acceptability.